Next Article in Journal
The Benefits of Physical Exercise on Mental Disorders and Quality of Life in Substance Use Disorders Patients. Systematic Review and Meta-Analysis
Previous Article in Journal
Improving Working Conditions and Job Satisfaction in Healthcare: A Study Concept Design on a Participatory Organizational Level Intervention in Psychosocial Risks Management
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association Between Gout and Injury Risk: A National Retrospective Cohort Study

1
Division of Nephrology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan
2
Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, New Taipei City 235, Taiwan
3
School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
4
Department of General Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan
5
Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
6
Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan
7
Division of Nephrology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan
8
School of Medicine, Buddhist Tzu Chi University, Hualien 970, Taiwan
9
Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan
10
School of Medicine, National Defense Medicine, Taipei 114, Taiwan
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2020, 17(10), 3679; https://doi.org/10.3390/ijerph17103679
Submission received: 5 April 2020 / Revised: 16 May 2020 / Accepted: 19 May 2020 / Published: 23 May 2020

Abstract

:
The association between gout and injury remains unclear. This study aimed to investigate the injury risk in patients with gout. Using the Longitudinal Health Insurance Database (LHID) from 2000 to 2010 in Taiwan, patients with gout (group CFG) and those without gout (group C) were enrolled for further analysis. The CFG group was separated into two subgroups (with and without medication) to determine whether the risk of injury was reduced with drug intervention. The follow-up period was defined as the time from the initial diagnosis of gout to the date of injury. A total of 257,442 individuals were enrolled in this study, with 85,814 people in group CFG and 171,628 people in group C. Using Cox regression analysis, group CFG showed a significant increase in the risk of injury. Traffic injuries, poisoning, falls, crushing/cutting/piercing injury, and suicides were prominent among these injuries. Furthermore, when urate-lowing drugs were used to treat the CFG group, there were no significant differences in the occurrence of injury. Patients with gout had an increased risk of injury overall, and drug intervention did not lower the risk of injury in these patients.

1. Introduction

Gout adversely affects joints by the deposition of monosodium urate monohydrate crystals and results in inflammatory arthritis. According to the National Health Research Institutes (NHRI), the prevalence of gout in Taiwan is 4.92%, significantly higher than that in other countries [1]. Patients with gout frequently suffer from multiple comorbidities, including hypertension (HTN), type II diabetes mellitus (DM), cardiovascular disease (CVD), chronic kidney disease (CKD), inflammation, dyslipidemia, and metabolic syndrome [2] in combination with Parkinson’s disease and pre-eclampsia [3].
In most countries worldwide, the occurrence of injury has gradually declined. However, injuries in general, increase morbidity and mortality and result in a huge expenditure for health insurance systems [4]. In Taiwan, the prevalence and incidence of injuries are also decreasing, but they play a major role in contributing to patient death. Injuries can be intentional or unintentional. Risk factors for the occurrence of injuries include chronic diseases (e.g., DM, CKD, orthostatic hypotension, cataracts) and lifestyle factors (e.g., walking stick, sleep duration, mental health) [5]. However, few studies have investigated the relationship between gout and the occurrence of injury.
Approximately one third of patients with incident gout have a comorbidity at diagnosis, such as DM or CKD [6]. Patients who have DM with peripheral neuropathy and neuropathic pain may display greater gait variability, contributing to falls and subsequent injuries [7]. CKD is associated with a decline in muscle mass, strength, and function, and may therefore increase the risk of subsequent injuries [8]. We hypothesized that the onset of gout would increase the risk of injuries, but few studies exist in this area. Therefore, the present study aimed to investigate whether gout directly increases the risk of injury in the Taiwanese population using the LHID from NHRI. Additionally, we examined if drug intervention lowers the risk of injury.

2. Materials and Methods

2.1. Data Collection

The LHID, established by the NHRI in Taiwan, collected data from subjects enrolled in the National Health Insurance (NHI) program. This was implemented in 1995. The present study collected data randomly selected from a cohort of 1 million subjects covered by the NHI. No statistical significance was observed in the distributions of age and sex between the cohorts in the LHID and the Taiwan NHI enrollees. The disease and diagnostic codes recorded in the registry of clinical visits and hospital care were based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). To maintain the privacy of subjects involved in the database, NHRI released data with encoded identification numbers; therefore, personnel without authorization were unable to reveal or link any direct information to the enrollees. This study (IRB number: TSGH IRB no. 2-105-05-082) was approved by the Ethics Review Board of the National Defense Medical Center and supervised in accordance with the tenets of the Declaration of Helsinki (1975) and its later amendment (2013). The requirement of informed consent was waived.

2.2. Study Design

To evaluate the risk of injury in patients with gout, an LHID from the year 2005 (LHID 2005) was used. This contained the registration and original claim data of 1,000,000 beneficiaries, randomly sampled from the Registry for Beneficiaries (ID) of the NHIR database from 1 January 2005, to 31 December 2005. Two groups were enrolled, and subjects were divided into those with gout (group CFG) and those without (group C). The inclusion criteria of group CFG were patients aged ≥18 years with a newly confirmed diagnosis of gout (ICD-9-CM 274.XX) between 2000 and 2010 and those visiting outpatient clinics at least thrice a year or hospitalized at least once for a confirmed diagnosis of gout. The year of gout diagnosis served as the index year. Regarding group C, subjects were randomly selected from LHID enrollees without a history of gout and were twice matched with group CFG according to sex, age, and index year. We used 1:2 matching to increase precision and hence power. Exclusion criteria were as follows: confirmed gout before 2000; diagnosis of hyperuricemia before tracking; occurrence of injury before tracking; sex unknown; and age <18 years. The endpoint was the occurrence of injury before subject withdrawal or the end of the follow-up (31 December 2010). Injuries for outcome measurement were defined as ICD-9-CM 800.XX to 999.XX, which include traffic accidents, accidental falls, and intentional and non-intentional injuries. Codes for the individual injury events includes traffic injuries (ICD-9-CM E800-E849), poisoning (ICD-9-CM E850-E869), falls (ICD-9-CM E880-E888), burns and fires (ICD-9-CM E890-E899), drowning (ICD-9-CM E910), suffocation (ICD-9-CM E911-E915), crushing/cutting/piercing (ICD-9-CM E916-E920), excessive heat (ICD-9-CM E900-E900.9), injury caused by animal (ICD-9-CM E906-E906.9), electric current injury (ICD-9-CM E925-E925.9), other unintentional injuries (ICD-9-CM E870-E879, E900-E909, E951-E949), suicide (ICD-9-CM E950-E959), homicide/abuse (ICD-9-CM E960-E969), and intention unknown (E980-E989). Hazard ratios of various injury causes between groups CFG and C were of great interest and were analyzed. We also used the Injury Severity Score (ISS) to assess the trauma severity of injury. ISS ≥16 is usually classified as major trauma and may result in poorer outcomes.
Confounding factors such as sex, age, comorbidities, resident location, and insurance premium were adjusted accordingly. Individuals with comorbidities before the index date were the study subjects. The comorbidities included diabetes mellitus (DM, ICD-9-CM 250), hypertension (ICD-9-CM 401-405), stroke (ICD-9-CM 430-438), chronic renal disease (CKD, ICD-9-CM 585), coronary artery disease (CAD, ICD-9-CM 410-414), liver cirrhosis (ICD-9-CM 570, 571, 572.1, 572.4, 573.1-573.3), chronic obstructive pulmonary disease (COPD, ICD-9-CM 491, 492, and 496), hyperlipidemia (ICD-9-CM 272.0, 272.2, 272.4), and cancer (ICD-9-CM 140-208). This study also evaluated whether urate-lowering drug intervention or compliance affected the risk of injury, including xanthine oxidase inhibitor allopurinol (Anatomical Therapeutic Chemical (ATC) code M04AA01), febuxostat (ATC code M04AA03), uricosuric agents probenecid (ATC code M04AB01), sulfinpyrazone (ATC code M04AB02), and benzbromarone (ATC code M04AB03)] as well as the uricase agent rasburicase (ATC code V03AF07). Medication compliance was calculated as the medication possession ratio (MPR; sum of days of supply of urate-lowering drugs divided by following up duration). We identified the good medication adherence subgroup as MPR > 80%, the intermittent adherence subgroup as MPR between 40% and 80%, and the poor adherence subgroup as MPR < 40%.

2.3. Data Analysis

Continuous variables were expressed as mean ± SD. Normally distributed continuous data between patients with and without gout, were compared by unpaired Student’s t-test/one-way ANOVA; nonparametric continuous data were analyzed by the Mann-Whitney U test/Kruskal–Wallis Test. Categorical variables were compared by χ2 analysis with Fisher’s exact correction. Cumulative risks of injury were calculated using the Kaplan–Meier method, and the differences in survival were determined by the log-rank test. Univariate and multivariable Cox proportional hazard regression analyses were used to determine the impact of gout on the occurrence of injury and identify other independent predictive variables for these events. p < 0.05 was considered statistically significant. The hazard ratios and confidence intervals (95%) from the Cox regression analyses were used as estimates of relative risk.

3. Results

3.1. Sample Size

As showed in Supplementary Figure S1, there was a total of 20,795,043 events from 2000 to 2010 in the Taiwan LHID. Around 986,713 individuals had medical records for visits to outpatient clinics, emergency departments, or hospitalization. Among them, 87,678 were diagnosed with gout, while 1864 were excluded. Overall, the study population totaled 257,442 in this retrospective matched cohort study for analysis, including 85,814 patients with gout (group CFG) and 171,628 without (group C). The incidences of injury in groups CFG and C were 18.92% and 17.83%, respectively, with significant differences (p < 0.001) in these two groups, as shown in Figure 1. Therefore, patients with gout had a higher risk of injury.

3.2. Baseline Characteristics

Table 1 presents demographics and comorbidities of groups CFG and C at the end of follow-up. The proportion of comorbidities, including DM, HTN, stroke, CKD, and coronary artery disease (CAD), was higher in group CFG than in group C (p < 0.001). Additionally, group CFG had a higher proportion of the population living in Central, Southern, and Eastern Taiwan, as well as in the outlying islands than group C (p < 0.001). Group CFG had a higher proportion in insurance premiums segment NT $15,841–25,000 than group C (p = 0.001).

3.3. Differences in Injuries between Groups CFG and C at the End of Follow-Up

Table 2 shows that the risk of injuries in group CFG was significantly higher at the end of follow-up (p < 0.001). Further analysis showed that the primary causes of classifiable injuries in both groups were falls, traffic injuries, and other unintentional injuries. In addition, group CFG suffered a more significant proportion of severe trauma when injury occurred (p < 0.001).

3.4. Risk Factors for the Occurrence of Injuries

As shown in Table 3, after variable adjustment, group CFG had a graver risk of injury (2034 times higher; p < 0.001). In addition, subjects with chronic renal disease displayed an enhanced risk of injury (1302 times higher; p < 0.001). Furthermore, subjects living in Central, Southern, and Eastern Taiwan, as well as in the outlying islands had a more significant risk of injury than those living in Northern Taiwan (1169–1201 times higher; p < 0.001). However, other chronic disease, such as diabetes mellitus, hypertension, stroke, or coronary artery disease, were not a significant risk factor of injury in our study.

3.5. Factors for the Occurrence of Injuries by Cox Regression Analysis

A stratified analysis of multiple variables performed to detect the risk of injury in the two groups is shown in Table 4. No statistical difference was found in the male (p < 0.001) and female (p < 0.001) groups, demonstrating that regardless of sex, the risk of injury was higher in group CFG. Similarly, the risk of injury was higher in group CFG than in group C with or without DM, HTN, stroke, CKD, or CAD (p < 0.001).
Additionally, regardless of the season, resident location, or insurance premium, the risk of injury was higher in group CFG (p < 0.001). Thus, people with gout had a higher association with the occurrence of injury, independent of other factors.

3.6. Relationship between the Occurrence of Subgroup Injuries and Gout

By performing an analysis of subgroups of injury at the end of the follow-up in Table 5, it was found that group CFG had an enhanced risk of traffic injuries, (1575 times higher), poisoning (1650 times higher), falls (1743 times higher), crushing/cutting/piercing (1879 times higher), suicide (1506 times higher), other unintentional injuries (1511 times higher), and not-provided E-code (1473 times higher) compared to group C (p < 0.001).

3.7. Difference in the Occurrence of Injuries in Group CFG with Medication (M) and without Medication (NM)

Group CFG was separated into two subgroups, those with medication (M) and those without medication (NM), as shown in Supplementary Figure S2. The incidence of injury was 18.76% in subgroup CFG-M and 19.96% in group CFG-NM, without significant differences (p = 0.232) between the two groups, as shown in Figure 2A. Group CFG-M was separated into three subgroups using the medication possession ratio (MPR): the incidence of injury in the poor adherence subgroup was 17.00%; in the intermittent adherence subgroup, 20.17%; and in the good adherence subgroup, 19.03%. No significant differences (p = 0.371) were found between the three groups in Figure 2B.

4. Discussion

To the best of our knowledge, this is the first national population-based cohort study to establish a substantial association between gout and injury. This study confirmed that patients with gout experienced an increased risk of injury. According to our data, four issues were highlighted: first, the enrollment of patients with gout was affected by significant parameters, such as residence, insurance premium, and comorbidity with other chronic diseases; second, risk factors for the occurrence of injuries in Taiwan include gout, chronic renal disease, and resident location; third, in patients with gout, there was a greater incidence of injuries such as traffic injury, falls, and other unintentional injuries; and finally, the intervention of urate-lowering drugs for patients with gout did not lower the risk of the injuries.
In the demographic data, subjects diagnosed with gout in Taiwan displayed significant parameters, such as resident location, insurance premium, and a higher proportion of other chronic diseases. In the Korea multicenter study, summer is the most common season of gout onset [9]. Similarly, a retrospective study in the United Kingdom found that the incidence of gout increased from April to September [10]. In the present study, gout attacks were found to occur particularly in summer and autumn. Regarding the seasonality of gout, previous evidence has proposed seasonal variations of urate, with higher serum levels during the summer months [11]. Changes in diet and increased alcohol consumption, enhanced physical activity and body temperature resulting in dehydration status, may contribute to the development of gout during this period. Regarding location, evidence from Taiwan has suggested that the development of gout maintains regional differences, particularly in the eastern coastal and offshore islands [12]. In the present study, similar findings were presented. A greater incidence of gout was determined particularly in central, southern, and eastern areas and in the outlying islands of Taiwan. As for chronic disease, in the present study, subjects with gout had a significantly higher risk of developing other comorbidities, including DM, HTN, stroke, and CAD. The results were compatible with previous findings from in vivo and in vitro studies, suggesting a strong association with serum uric acid levels, cardiovascular diseases, CKD, and stroke [13,14]. Hyperuricemia may induce oxidative stress [15], stimulate an inflammatory response [16], and cause endothelial dysfunction [17]. A recent study also revealed a connection between hyperuricemia and an increased risk of cardiovascular mortality [18]. In summary, findings in subjects in group CFG display unique correlations with season, residence, and comorbidities; physicians should be alert to these associations when treating patients with hyperuricemia and gout.
In the present study, demographic data and morbidities were analyzed for relationships with the occurrence of injury. The incidence of injury was significantly correlated with patients with gout in terms of chronic renal disease and resident location. Gout is usually associated with long-lasting, abnormally high amounts of uric acid in the blood. It is a painful condition involving the joints, like arthritis. Therefore, a sudden onset of gout may cause gait instability, contributing to falls and subsequent injuries. Another condition, chronic progressive tophaceous arthritis, also causes joint damage, bone destruction and deformity, and may increase the risk of subsequent injuries [19]. Regarding renal disease, injury from falls has been proven to be associated with CKD, particularly in elderly patients undergoing hemodialysis [20]. Polypharmacy, anemia, vitamin D deficiency, sarcopenia, fluid status change, and posture hypotension all potentially contribute to the higher incidence of injury in this group. As we did not further classify the stages of renal diseases in this study, an additional large cohort study is needed to analyze the relationship between CKD stages and the occurrence of injury. Furthermore, regarding resident location, a previous study suggested a significant association among health, lifestyle, and behavior with the development of injury [21]. An inconvenient living environment and poorer medical care is associated with an elevated incidence of injury. Our findings confirmed that location is a risk factor for the occurrence of gout and injuries.
Among the causes of injury, we found that traffic, poisoning, falls, crushing, cutting, piercing, other unintentional injuries, and suicides were significantly higher in people with gout. Patients with gout may display a significant decrease in walking velocity, cadence, and stride length during periods of joint pain. Antalgic gait may increase the risk of traffic injury and falls. When chronic tophi affect the movement and flexibility of the joints, the risk of cutting, piercing, and crushing may also increase. In addition, steroid treatment for gout may induce muscle weakness and osteoporosis and increase the incidence of injury. A recent meta-analysis demonstrated a strong positive relationship between gout and depression [22]. We can reasonably speculate that the greater incidence of suicide and poisoning in gout patients is related to depressive disorders. Our findings emphasize the importance of developing national preventive programs designed to reduce the incidence of injury in patients with gout based on the risk factors.
Intervention with drugs in patients with gout did not lower the risk of injury. Hyperuricemia is the underlying condition accelerating gout and the long-term treatment of it involves the therapeutic lowering of serum and tissue uric acid levels. In 2012, the American College of Rheumatology published its first treatment guidelines. It reasserted that chronic gout needed persistent treatment, and integrated the issues of anti-inflammation, urate-lowering therapy (ULT), and lifestyle risk management [23]. However, in the present study, drug intervention with ULT and drug compliance did not lower the risk of injury in this group. There is a possibility that when subjects were diagnosed with gout, they had already suffered irreversible joint damage because of long-term hyperuricemia-associated comorbidities. After the occurrence of unexpected events, the treatment for gout was inadequate. Further strict randomized control trials are required to explore the real connection and impacts.
There are some limitations to our study. First, the NHIR database does not provide personal history and lifestyle information of patients, such as smoking, drinking, body mass index, and functional capacity. These are the potential confounding factors for this study. In addition, all definitions of variables were based on clinical physicians’ diagnosis and coding; therefore, any misidentification may result in study bias. Second, people with hypertension, diabetes mellitus, stroke, and coronary artery disease did not show an elevated risk of injuries in our studies. This result is unexpected and may differ from previous studies. We believe that this result requires further analysis of the injury subgroup to confirm these findings. Third, we did not analyze the type of medication used in the study or in the comparison cohort due to technical limitations for data retrieval. In addition, we could not evaluate the severity of gout or the interaction with medication use. Fourth, we did not analyze the multiple injury events, which is an important issue in epidemiology studies. Lastly, most injury severity data are unavailable in the NHIR database. Although ISS ≥16 points was employed as the basis to present the severity of patients with trauma, not every injury event was scored.

5. Conclusions

Physicians and government policymakers should remain alert to the risk of injury in patients with gout and initiate early therapeutic strategies. The present national population-based cohort study supports the view that gout may directly increase the risk of injury. Although urate-lowing drug intervention did not curtail the incidence of injury in the present study, further research is required to clarify this finding.

Supplementary Materials

The following are available online at https://www.mdpi.com/1660-4601/17/10/3679/s1, Figure S1: Flowchart of enrollment of patients with gout (group CGF), matched with those without gout (group C), Figure S2: Flowchart of enrollment of injured patients on medication and those without medication.

Author Contributions

Conceptualization and methodology, J.-S.C. and W.-C.C.; writing—original draft preparation, S.-H.O. and C.-L.C.; writing—review and editing, C.-W.L.; supervision, T.-C.F. and K.-C.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the Ministry of Science and Technology Project (MOST 107-2314-B-075B-010-MY3), the Kaohsiung Veterans General Hospital Research Foundation (VGHKS MAB-108-048), and the Tri-Service General Hospital Research Foundation (TSGH-B-109010).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kuo, C.F.; Grainge, M.J.; Zhang, W.; Doherty, M. Global epidemiology of gout: Prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 2015, 11, 649–662. [Google Scholar] [CrossRef]
  2. Joo, K.; Kwon, S.R.; Lim, M.J.; Jung, K.H.; Joo, H.; Park, W. Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. J. Korean Med. Sci. 2014, 29, 657–661. [Google Scholar] [CrossRef] [Green Version]
  3. Wandell, P.; Carlsson, A.C.; Ljunggren, G. Gout and its comorbidities in the total population of Stockholm. Prev. Med. 2015, 81, 387–391. [Google Scholar] [CrossRef] [PubMed]
  4. Fonseca, S.S.; Victora, C.G.; Halpern, R.; Barros, A.J.; Lima, R.C.; Monteiro, L.A.; Barros, F. Risk factors for accidental injuries in preschool children. J. Pediatr. 2002, 78, 97–104. [Google Scholar] [CrossRef]
  5. Zhang, H.; Wei, F.; Han, M.; Chen, J.; Peng, S.; Du, Y. Risk factors for unintentional injuries among the rural elderly: A county-based cross-sectional survey. Sci. Rep. 2017, 7, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Kuo, C.F.; Luo, S.F. Gout: Risk of premature death in gout unchanged for years. Nat. Rev. Rheumatol. 2017, 13, 200. [Google Scholar] [CrossRef] [PubMed]
  7. Lalli, P.; Chan, A.; Garven, A.; Midha, N.; Chan, C.; Brady, S.; Block, E.; Hu, B.; Toth, C. Increased gait variability in diabetes mellitus patients with neuropathic pain. J. Diabetes Complicat. 2013, 27, 248–254. [Google Scholar] [CrossRef] [PubMed]
  8. Avin, K.G.; Moorthi, R.N. Bone is not alone: The effects of skeletal muscle dysfunction in chronic kidney disease. Curr. Osteoporos. Rep. 2015, 13, 173–179. [Google Scholar] [CrossRef] [Green Version]
  9. Choi, H.J.; Lee, C.H.; Lee, J.H.; Yoon, B.Y.; Kim, H.A.; Suh, C.H.; Choi, S.T.; Song, J.S.; Joo, H.; Choi, S.J.; et al. Seasonality of gout in Korea: A multicenter study. J. Korean Med. Sci. 2015, 30, 240–244. [Google Scholar] [CrossRef] [Green Version]
  10. Elliot, A.J.; Cross, K.W.; Fleming, D.M. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994–2007. Ann. Rheum. Dis. 2009, 68, 1728–1733. [Google Scholar] [CrossRef]
  11. Åkerblom, A.; Helmersson-Karlqvist, J.; Weitoft, T.; Larsson, A. Seasonal variations of urate in a Swedish adult population. Clin. Rheumatol. 2017, 36, 1595–1598. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Kuo, C.F.; Grainge, M.J.; See, L.C.; Yu, K.H.; Luo, S.F.; Zhang, W.; Doherty, M. Epidemiology and management of gout in Taiwan: A nationwide population study. Arthritis Res. Ther. 2015, 17, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Odden, M.C.; Amadu, A.R.; Smit, E.; Lo, L.; Peralta, C.A. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988–1994 and 1999–2002. Am. J. Kidney Dis. 2014, 64, 550–557. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Sharaf El Din, U.A.A.; Salem, M.M.; Abdulazim, D.O. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review. J. Adv. Res. 2017, 8, 537–548. [Google Scholar] [CrossRef]
  15. Cristóbal-García, M.; García-Arroyo, F.E.; Tapia, E.; Osorio, H.; Arellano-Buendía, A.S.; Madero, M.; Rodríguez-Iturbe, B.; Pedraza-Chaverrí, J.; Correa, F.; Zazueta, C.; et al. Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension. Oxid. Med. Cell. Longev. 2015, 2015, 535686. [Google Scholar] [CrossRef] [Green Version]
  16. Cai, W.; Duan, X.M.; Liu, Y.; Yu, J.; Tang, Y.L.; Liu, Z.L.; Jiang, S.; Zhang, C.P.; Liu, J.Y.; Xu, J.X. Uric acid induces endothelial dysfunction by activating the HMGB1/RAGE signaling pathway. Biomed. Res. Int. 2017. [Google Scholar] [CrossRef]
  17. Kanbay, M.; Segal, M.; Afsar, B.; Kang, D.H.; Rodriguez-Iturbe, B.; Johnson, R.J. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart 2013, 99, 759–766. [Google Scholar] [CrossRef] [Green Version]
  18. Johnson, R.J.; Bakris, G.L.; Borghi, C.; Chonchol, M.B.; Feldman, D.; Lanaspa, M.A.; Merriman, T.R.; Moe, O.W.; Mount, D.B.; Lozada, L.G.; et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: Report of a scientific workshop organized by the National Kidney Foundation. Am. J. Kidney Dis. 2018, 71, 851–865. [Google Scholar] [CrossRef]
  19. Stewart, S.; Dalbeth, N.; Vandal, A.C.; Rome, K. The first metatarsophalangeal joint in gout: A systematic review and meta-analysis. BMC Musculoskelet. Disord. 2016, 17, 69. [Google Scholar] [CrossRef] [Green Version]
  20. López-Soto, P.J.; De Giorgi, A.; Senno, E.; Tiseo, R.; Ferraresi, A.; Canella, C.; Rodríguez-Borrego, M.A.; Manfredini, R.; Fabbian, F. Renal disease and accidental falls: A review of published evidence. BMC Nephrol. 2015, 16, 176. [Google Scholar] [CrossRef] [Green Version]
  21. Kwan, M.M.; Close, J.C.; Wong, A.K.; Lord, S.R. Falls incidence, risk factors, and consequences in Chinese older people: A systematic review. J. Am. Geriatr. Soc. 2011, 59, 536–543. [Google Scholar] [CrossRef] [PubMed]
  22. Lin, S.; Zhang, H.; Ma, A. Association of gout and depression: A systematic review and meta-analysis. Int. J. Geriatr. Psychiatry 2018, 33, 441–448. [Google Scholar] [CrossRef] [PubMed]
  23. Igel, T.F.; Krasnokutsky, S.; Pillinger, M.H. Recent advances in understanding and managing gout. F1000Research 2017, 6, 247. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Kaplan–Meier analysis for cumulative risk of injury among patients aged 18 and over stratified by gout with log-rank test.
Figure 1. Kaplan–Meier analysis for cumulative risk of injury among patients aged 18 and over stratified by gout with log-rank test.
Ijerph 17 03679 g001
Figure 2. Kaplan–Meier analysis for (A) cumulative risk of injury among patients with gout and over, stratified by intervention of medications with the log-rank test and (B) cumulative risk of injury among patients with gout and over, stratified by adherence of medications (MPR) with the log-rank test.
Figure 2. Kaplan–Meier analysis for (A) cumulative risk of injury among patients with gout and over, stratified by intervention of medications with the log-rank test and (B) cumulative risk of injury among patients with gout and over, stratified by adherence of medications (MPR) with the log-rank test.
Ijerph 17 03679 g002
Table 1. Demographic and Comorbidities of Patients with Gout (Group CFG) and Without (Group C).
Table 1. Demographic and Comorbidities of Patients with Gout (Group CFG) and Without (Group C).
GoutTotalGroup CFGGroup Cp Value
Variables n%n%n%
Total257,442 85,81433.33171,62866.67
Sex 0.999
Male206,90780.3768,96980.37137,93880.37
Female50,53519.6316,84519.6333,69019.63
Age (Years) (Mean ± SD)64.15 ± 16.6963.90 ± 16.1364.28 ± 16.970.041
Season <0.001
Spring (March–May)62,93924.4519,67222.9243,26725.21
Summer (June–August)64,59025.0921,97425.6142,61624.83
Autumn (September–November)68,32726.5424,95229.0843,37525.27
Winter (December–February)61,58623.9219,21622.3942,37024.69
Location <0.001
Northern Taiwan101,63939.4832,54737.9369,09240.26
Central Taiwan73,30428.4724,92929.0548,37528.19
Southern Taiwan64,73425.1521,63725.2143,09725.11
Eastern Taiwan16,5646.4362087.2310,3566.03
Outlying islands12010.474930.577080.41
Insured Premium (NT$) 0.001
<15,840253,90098.6284,51798.49169,38398.69
15,841–25,00028321.1010771.2617551.02
≥25,0017100.282200.264900.29
Diabetes Mellitus (DM) <0.001
Without212,84682.6869,79781.34143,04983.35
With44,59617.3216,01718.6628,57916.65
Hypertension <0.001
Without197,47276.7156,90666.31140,56681.90
With59,97023.2928,90833.6931,06218.10
Stroke <0.001
Without233,00390.5177,09889.84155,90590.84
With24,4419.49871810.1615,7239.16
Chronic Renal Disease <0.001
Without248,62296.5782,48696.12166,13696.80
With88203.4333283.8854923.20
Coronary Artery Disease (CAD) <0.001
Without230,45689.5275,33687.79155,12090.38
With26,98610.4810,47812.2116,5089.62
p-value (category variable: Chi-square/Fisher’s exact test; continue variable: independent t-test); DM: ICD-9-CM 250; Hypertension: ICD-9-CM 401-405; Stroke: ICD-9-CM 430-438; Chronic renal disease: ICD-9-CM 585; CAD: ICD-9-CM 410-414.
Table 2. Differences in Injuries between Patients with Gout (Group CFG) and Without (Group C).
Table 2. Differences in Injuries between Patients with Gout (Group CFG) and Without (Group C).
GoutTotalGroup CFGGroup Cp Value
Variables n%n%n%
Total257,442 85,81433.33171,62866.67
Injury <0.001
Without210,61081.8169,57681.08141,03482.17
With46,83218.1916,23818.9230,59417.83
Cause of injury <0.001
Traffic Injuries661514.12214113.19447414.62
Poisoning5861.252341.443521.15
Falls10,04421.45332220.46672221.97
Burns and Fires730.16190.12540.18
Drowning90.0230.0260.02
Suffocation2170.46680.421490.49
Crushing/Cutting/Piercing14523.105123.159403.07
Excessive Heat120.0340.0280.03
Injury Caused by Animals960.03440.05520.03
Electric Current Injury210.0440.02170.06
Other Unintentional Injuries947220.23376823.20570418.64
Suicide5551.191791.103761.23
Homicide/Abuse4490.961400.863091.01
Intention Unknown3050.651100.681950.64
No Provided E-Code16,92636.14569035.0411,23636.73
Injury Severity Score (ISS) ≥ 16 <0.001
Without257,05699.8585,63199.79171,42599.88
With3860.151830.212030.12
p-value (category variable: Chi-square/Fisher’s exact test; continue variable: independent t-test).
Table 3. Risk Factors for the Occurrence of Injuries.
Table 3. Risk Factors for the Occurrence of Injuries.
VariablesCrude HR95% CI95% CIpAdjusted HR95% CI95% CIp
Gout
WithoutReference Reference
With1.9921.9532.031<0.0012.0341.9952.074<0.001
Sex
Male0.9120.8920.932<0.0010.8890.8690.909<0.001
FemaleReference Reference
Age (Years)0.9890.9880.990<0.0010.9930.9920.994<0.001
Diabetes Mellitus (DM)
WithoutReference Reference
With0.8560.8360.876<0.0010.8940.8730.916<0.001
Hypertension
WithoutReference Reference
With0.7510.7350.768<0.0010.7870.7690.806<0.001
Stroke
WithoutReference Reference
With0.6180.5960.642<0.0010.6490.6260.674<0.001
Chronic Renal Disease
WithoutReference Reference
With1.4841.4221.548<0.0011.3021.2471.360<0.001
Coronary Artery Disease (CAD)
WithoutReference Reference
With0.6120.5920.633<0.0010.6610.6390.685<0.001
Season
Spring (March–May)Reference Reference
Summer (June–August)0.9440.9200.968<0.0010.9320.9090.956<0.001
Autumn (September–November)0.8130.7920.834<0.0010.8030.7830.824<0.001
Winter (December–February)0.9110.8870.935<0.0010.9190.8960.943<0.001
Location
Northern TaiwanReference Reference
Central Taiwan1.2281.2011.256<0.0011.1691.1431.196<0.001
Southern Taiwan1.2151.1861.243<0.0011.1841.1561.212<0.001
Eastern Taiwan1.3141.2681.361<0.0011.2011.1591.245<0.001
Outlying Islands1.3131.1561.492<0.0011.1741.0331.3340.014
Insured premium (NT$)
<15,840Reference Reference
15,841–25,0000.9800.9031.0630.6220.8990.8280.9750.010
≥25,0010.7180.5720.9020.0040.6220.4950.782<0.001
HR = hazard ratio, CI = confidence interval, Adjusted HR: Adjusted variables listed in Table 1. DM: ICD-9-CM 250; Hypertension: ICD-9-CM 401-405; Stroke: ICD-9-CM 430-438; Chronic renal disease: ICD-9-CM 585; CAD: ICD-9-CM 410-414.
Table 4. Factors for the Occurrence of Injuries Stratified by Variable Listed in Table 1 by Cox Regression Analysis.
Table 4. Factors for the Occurrence of Injuries Stratified by Variable Listed in Table 1 by Cox Regression Analysis.
GoutGroup CFGGroup CRatioAdjusted HR95%CI95%CIp
Variables EventPYsRate (per 105 PYs)EventPYsRate (per 105 PYs)
Total16,238150,342.0810,800.7030,594322,350.399490.911.1382.0341.9952.074<0.0011
Sex
Male12,534118,736.1410,556.1823,960256,463.939342.441.1302.0211.9762.066<0.001
Female370431,605.9411,719.32663465,886.4610,068.841.1642.0771.9932.165<0.001
Diabetes mellitus (DM)
Without13,201116,597.0211,321.9024,862254,643.699763.451.1602.0822.0372.127<0.001
With303733,745.068999.84573267,706.708465.931.0631.8341.7531.919<0.001
Hypertension
Without11,73698,684.3911,892.4624,703238,757.7110,346.471.1492.0001.9552.045<0.001
With450251,657.698715.06589183,592.687047.271.2372.1842.0972.274<0.001
Stroke
Without15,258134,176.2011,371.6128,531284,544.6010,026.901.1342.0602.0192.103<0.001
With98016,165.886062.15206337,805.795456.841.1111.6671.5421.802<0.001
Chronic renal disease
Without15,325143,313.2010,693.3629,281307,574.559519.971.1232.0762.0352.119<0.001
With9137028.8912,989.25131314,775.848886.131.4621.4921.3681.627<0.001
Coronary artery disease (CAD)
Without14,873129,957.1311,444.5428332284,501.309958.481.1492.0391.9982.082<0.001
With136520,384.956696.12226237,849.095976.371.1201.9401.8102.079<0.001
Season
Spring (March–May)396733,203.3511,947.59776075,299.8610,305.461.1592.0611.9812.143<0.001
Summer (June–August)427137,283.1211,455.59779280,649.669661.541.1862.0962.0162.178<0.001
Autumn (September–November)432645,283.449553.16759089,206.108508.391.1231.9851.9102.063<0.001
Winter (December–February)367434,572.1810,627.04745277,194.779653.501.1011.9991.9192.082<0.001
Location
Northern Taiwan532655,338.619624.3810,761127,610.688432.681.1412.0742.0042.145<0.001
Central Taiwan514744,678.2711,520.14925991,204.0910,151.961.1352.0822.0102.156<0.001
Southern Taiwan427737,643.4011,361.89807579,540.4610,152.071.1191.9671.8942.043<0.001
Eastern Taiwan139111,782.5511,805.59235721,562.3910,931.071.0801.9321.8042.069<0.001
Outlying Islands97899.2610,786.651422432.785836.941.8481.7791.3582.330<0.001
Insured premium (NT$)
<15,84015,975147,884.4810,802.3530,197317,543.949509.551.1362.0291.9892.069<0.001
15,841–25,0002382122.2711,214.413484087.908512.931.3172.5392.1363.020<0.001
≥25,00125335.337455.3449718.566819.191.0932.9461.6955.121<0.001
PYs = Person-years; Adjusted HR = Adjusted Hazard ratio: Adjusted for variables listed in Cox Regression; CI = confidence interval; DM: ICD-9-CM 250; Hypertension: ICD-9-CM 401-405; Stroke: ICD-9-CM 430-438; Chronic renal disease: ICD-9-CM 585; CAD: ICD-9-CM 410-414.
Table 5. Relationship between the Occurrence of Subgroup Injuries in Patients with Gout (Group CFG) and Without Gout (Group C).
Table 5. Relationship between the Occurrence of Subgroup Injuries in Patients with Gout (Group CFG) and Without Gout (Group C).
GoutGroup CFGGroup CRatioAdjusted HR95%CI95%CIp
Subgroups of Injury EventPYsRate (per 10 5 PYs)EventPYsRate (per 10 5 PYs)
Total16,238150,342.0810,800.7030,594322,350.399,490.911.1382.0341.9952.074<0.001
Cause of injury
Traffic injuries2141150,342.081424.094,74322,350.391387.931.0261.5751.4941.861<0.001
Poisoning234150,342.08155.65352322,350.39109.201.4251.6501.3821.970<0.001
Falls3322150,342.082209.636722322,350.392085.311.0601.7431.6701.820<0.001
Burns and fires19150,342.0812.6454322,350.3916.750.7540.6370.2158.1890.721
Drowning3150,342.082.006322,350.391.861.0721.0220.6743.5710.166
Suffocation68150,342.0845.23149322,350.3946.220.9790.9420.3282.5540.402
Crushing/Cutting/Piercing512150,342.08340.56940322,350.39291.611.1681.8791.6622.123<0.001
Excessive Heat4150,342.082.668322,350.392.481.0721.1450.9762.4470.435
Injury Caused by Animals44150,342.0829.2752322,350.3916.131.8141.9761.0133.0010.026
Electric Current Injury4150,342.082.6617322,350.395.270.5040.9760.4321.4340.556
Other Unintentional Injuries3768150,342.082506.285704322,350.391769.501.4161.5111.1262.138<0.001
Suicide179150,342.08119.06376322,350.39116.641.0211.5061.2471.820<0.001
Homicide/Abuse140150,342.0893.12309322,350.3995.860.9710.6180.3011.0120.058
Intention Unknown110150,342.0873.17195322,350.3960.491.2091.4471.1191.8760.005
No Provided E-Code5690150,342.083784.7011,236322,350.393485.651.0861.4731.4261.552<0.001
Injury Severity Score (ISS) ≥16
Without16,055150,342.0810,678.9830,391322,350.399427.941.1332.0251.9862.066<0.001
With183150,342.08121.72203322,350.3962.971.9332.1141.6922.641<0.001
PYs = Person-years; Adjusted HR = Adjusted Hazard ratio: Adjusted for the variables listed in Cox regression in Table 1; CI = confidence interval.

Share and Cite

MDPI and ACS Style

Ou, S.-H.; Chou, C.-L.; Lin, C.-W.; Chien, W.-C.; Fang, T.-C.; Lu, K.-C.; Chen, J.-S. Association Between Gout and Injury Risk: A National Retrospective Cohort Study. Int. J. Environ. Res. Public Health 2020, 17, 3679. https://doi.org/10.3390/ijerph17103679

AMA Style

Ou S-H, Chou C-L, Lin C-W, Chien W-C, Fang T-C, Lu K-C, Chen J-S. Association Between Gout and Injury Risk: A National Retrospective Cohort Study. International Journal of Environmental Research and Public Health. 2020; 17(10):3679. https://doi.org/10.3390/ijerph17103679

Chicago/Turabian Style

Ou, Shih-Hsiang, Chu-Lin Chou, Chia-Wei Lin, Wu-Chien Chien, Te-Chao Fang, Kuo-Cheng Lu, and Jin-Shuen Chen. 2020. "Association Between Gout and Injury Risk: A National Retrospective Cohort Study" International Journal of Environmental Research and Public Health 17, no. 10: 3679. https://doi.org/10.3390/ijerph17103679

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop